Omniab, Inc. · NASDAQ:OABI
Omniab — Q2 2026 Earnings Presentation
24 slides from Omniab's earnings presentation, Aug 6, 2026
Slide 1: Q2 2026 Financial Results & Business Update
1 Q2 2026 Financial Results & Business Update Nasdaq: OABI August 6, 2026
Slide 2: Disclaimer
2 Disclaimer We caution you that this presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, including our financial guidance fo
Slide 3: Introduction - Matt Foehr
Omni Introduction - Matt Foehr
Slide 4: Q2 Highlights
4 Q2 Highlights Clinical-stage partner pipeline advancement driving milestone payments Building a strong foundation for xPloration®, view as a complement to our licensing business OmniAb's novel technologies positioned to have important impacts on our business and our industry Continued strong partn
Slide 5: Novel Technology Poised for Value Creation
5 Novel Technology Poised for Value Creation DIVERSIFYING REVENUE OPPORTUNITIES Sale of two instruments in Q2 Competitively-priced instrument Through on-going discussions with Proprietary, single-use consumables partners and market research, seeing Annual software subscription increased market oppor
Slide 6: Active Partners
6 Active Partners Number of Active Partners(1)(2) Partner Type 110 Academic 5% 100 Commercial 20% • 110 Active Partners as of 6/30/2026 Discovery 75% n=110 • New licenses added in Q2 included EnRosa Therapeutics and argenx 50 Partner Location(3) Middle East 1% APAC 20% • 8 of the 10 largest global p
Slide 7: Active Programs
7 Active Programs Number of YTD 2026 Change in 500 Active Programs(1) Active Programs 25 425 425 • 425 Active Programs as of 407 6/30/2026 400 (7) • >98% of our Active Programs 300 have contracted future economics to OmniAb 200 • Over $3 billion in total contracted potential milestones(2) 100 • Aver
Slide 8: Active Clinical Programs and Approved Products
8 Active Clinical Programs and Approved Products Number of Active Clinical Programs and Approved Products(1)(2) 34 • 34 active clinical programs and approved products as of 6/30/2026 30 ‒ OmniRat®, OmniFlic® and OmniChicken®-derived programs were added in Q2(3) • Four new clinical additions so far i
Slide 9: Clinical and Commercial-Stage Partner Pipeline
Clinical and Commercial-Stage Partner Pipeline 9 (1)(2) AS OF 6/30/2026 ONLY PROGRAMS WITH DOWNSTREAM ECONOMICS ARE SHOWN Phase Phase Phase11 1/1b Phase 1/2 1/2 Phase 2 Phase 3 Registration Approved 1/1b Hanall Biopharma CStone Pharmaceuticals, Zhikang Hongyi (Biocity) CessationTherapeutics Zhikang
Slide 10: Select Partner Updates
10 Select Partner Updates(1) IMVT-1402 TEV-’408 Precemtabart tocentecan Other Partner Program FcRn IL-15 CEACAM5 ADC Progression Updates IMVT-1402 showed clinically meaningful Teva announced plan to advance TEV- At the American Society of Clinical response rates of 72.7% ACR20, 54.5% ’408, an invest
Slide 11: Upcoming Partner Program Clinical/Regulatory Events
Upcoming Partner Program Clinical/Regulatory Events 11 POTENTIAL EVENTS IN SECOND HALF OF 2026(1) Clinical Data Events Regulatory Action/Market Entry Teva Immunovant Salubris TEV-’408 IMVT-1402 SAL003 IL-15 FcRn PCSK9 Celiac Disease(2) Difficult-to-Treat Hypercholesterolemia/ Phase 2a Rheumatoid Art
Slide 12: Upcoming Events and Presentations
12 Upcoming Events and Presentations Investor & Analyst Day Hybrid event (In-person/webcast) live October 6th @ 8 am PT/11 am ET from our Emeryville, CA Headquarters Management presentations, xPloration® demonstrations, Q&A and in-person lab tours (Registration Required) October 20th November 4th Vi
Slide 13: Financial Updates - Kurt Gustafson
13 Financial Updates Kurt Gustafson
Slide 14: Q2 2026 Revenue
14 Q2 2026 Revenue $ in millions $15 $13.4 xPloration • License and Milestone revenue increased due to an increase in milestone revenue $10 License & • xPloration revenue increased primarily as a result of Milestone increased instrument sales $5 $3.9 • Service revenue increased due to new ion channe
Slide 15: June 2026 YTD Revenue
15 June 2026 YTD Revenue $ in millions $30 $27.8 xPloration • License and Milestone revenue increased due to an increase in milestone revenue $20 License & Milestone • xPloration revenue increased primarily as a result of increased instrument sales $10 $8.1 xPloration • Service revenue increased due
Slide 16: Q2 2026 Costs and Operating Expense (GAAP)
16 Q2 2026 Costs and Operating Expense (GAAP) $ in millions $25 • R&D expense decreased primarily due to lower personnel expenses related to share-based $20.1 $20.1 $20 compensation and salaries, as well as facility-related Other Other costs $15 G&A • G&A expense decreased primarily due to lower G&A
Slide 17: June 2026 YTD Costs and Operating Expense (GAAP)
17 June 2026 YTD Costs and Operating Expense (GAAP) $ in millions $50 • R&D expense decreased primarily due to lower $43.1 personnel expenses related to share-based $42.3 compensation and salaries, lower external expenses Other associated with the completion of certain legacy Write-off (Q1) Other sm
Slide 18: Q2 2026 and June 2026 YTD Financial Results
18 Q2 2026 and June 2026 YTD Financial Results 2025 2026 Q2 2025 Q2 2026 Variance Variance (in millions, except per share data) YTD YTD License and milestone revenue $ 1.2 $ 9.5 $ 8.3 $ 3.3 $ 21.5 $ 18.2 Service revenue 1.9 2.5 0.6 3.8 4.6 0.8 xPloration revenue 0.6 1.2 0.6 0.7 1.2 0.5 Royalty reven
Slide 19: Q2 2026 Cash Costs and Operating Expense (Non-GAAP)
19 Q2 2026 Cash Costs and Operating Expense (Non-GAAP) GAAP TO NON-GAAP RECONCILIATION (in millions) Q2 2025 Q2 2026 2025 YTD 2026 YTD Costs and operating expenses (GAAP) $20.1 $20.1 $43.1 $42.3 Less: Depreciation of property and equipment 0.9 0.6 1.8 1.2 Less: Amortization of intangible assets 3.2
Slide 20: Balance Sheet
20 Balance Sheet (in millions) December 31, June 30, 2025 2026 ASSETS Current assets: Cash & investments $ 54.0 $ 52.0 Accounts receivable, net 7.4 10.3 Other current assets 3.9 3.7 Goodwill & intangible assets 209.1 200.1 PPE & leases 25.0 22.9 Other assets 1.5 1.3 Total assets $ 300.9 $ 290.3 LIAB
Slide 21: Updated 2026 Guidance
21 Updated 2026 Guidance • We now expect Total Revenue to be in the range of $32 to $36 million • We now expect Costs and Operating Expense to be in the range of $84 to $88 million • We now expect Cash Costs and Operating Expense(1) to be in the range of $51 to $55 million • We now expect year-end c
Slide 22: Strong Financial Performance: Update to 2026 Guidance
22 Strong Financial Performance UPDATE TO 2026 GUIDANCE in millions Costs & Cash Costs & Revenue Operating Expense Operating Expense(1) Cash Use $40 $100.9 $40 $38.9 $32-$36 $100 $100 $28-$33 $87.6 $83-$88 $84-$88 $33.3 $26.4 $60.3 $50-$55 $51-$55 $16-$21 $18.7 $51.7 $20 $50 $50 $20 $13-$17 $0 $0 $0
Slide 23: Q&A
23 Q&A Matt Foehr Kurt Gustafson Amechi Nwachuku CEO CFO COO
Slide 24: Omni >
Omni >